Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL

Nature Medicine

Volumn 19, Issue 3, 2013, Pages 368-371

  Tzoneva, Gannie ^a   Perez Garcia, Arianne ^a   Carpenter, Zachary ^a   Khiabanian, Hossein ^a   Tosello, Valeria ^b   Allegretta, Maddalena ^a   Paietta, Elisabeth ^c   Racevskis, Janis ^c   Rowe, Jacob M ^d,e   Tallman, Martin S ^f   Paganin, Maddalena ^g   Basso, Giuseppe ^g   Hof, Jana ^h   Kirschner Schwabe, Renate ^h   Palomero, Teresa ^a,i   Rabadan, Raul ^a   Ferrando, Adolfo ^a,i  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e SHAARE ZEDEK MEDICAL CENTER   (Israel)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF PADOVA   (Italy)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ANTINEOPLASTIC AGENT; MERCAPTOPURINE; NT5C2 NUCLEOTIDASE; NUCLEOSIDE ANALOG; NUCLEOTIDASE; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOBLAST; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

5'-NUCLEOTIDASE; 6-MERCAPTOPURINE; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; BASE SEQUENCE; CELL LINE; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SEQUENCE ANALYSIS, DNA; THIOGUANINE;

EID: 84875158235     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3078     Document Type: Article

References (37)

1. Möricke, A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24, 265-284 (2010).
2. Salzer, W.L. et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia 24, 355-370 (2010).
3. Koren, G. et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N. Engl. J. Med. 323, 17-21 (1990).
4. Relling, M.V., Hancock, M.L., Boyett, J.M., Pui, C.H. & Evans, W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93, 2817-2823 (1999).
5. Pui, C.H. & Evans, W.E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166-178 (2006).
6. Tallen, G. et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J. Clin. Oncol. 28, 2339-2347 (2010).
7. Gaynon, P.S. et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse-the Children's Cancer Group Experience. Cancer 82, 1387-1395 (1998).
8. Tosello, V. et al. WT1 mutations in T-ALL. Blood 114, 1038-1045 (2009).
9. Mullighan, C.G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008).
10. Clappier, E. et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J. Exp. Med. 208, 653-661 (2011).
11. Thompson, B.J. et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835 (2007).
12. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
13. Jalota, A. et al. Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. J. Biol. Chem. 280, 16019-16029 (2005).
14. Zhang, Y. et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 23, 8902-8912 (2003).
15. Hof, J. et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 29, 3185-3193 (2011).
16. Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
17. Lübbert, M. et al. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 75, 1163-1169 (1990).
18. Van Vlierberghe, P. et al. ETV6 mutations in early immature human T cell leukemias. J. Exp. Med. 208, 2571-2579 (2011).
19. Coustan-Smith, E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147-156 (2009).
20. Oka, J., Matsumoto, A., Hosokawa, Y. & Inoue, S. Molecular cloning of human cytosolic purine 5′-nucleotidase. Biochem. Biophys. Res. Commun. 205, 917-922 (1994).
21. Spychała, J., Madrid-Marina, V. & Fox, I.H. High Km soluble 5′-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. J. Biol. Chem. 263, 18759-18765 (1988).
22. Brouwer, C. et al. Role of 5′-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment. Clin. Chim. Acta 361, 95-103 (2005).
23. Hunsucker, S.A., Mitchell, B.S. & Spychala, J. The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107, 1-30 (2005).
24. Galmarini, C.M., Jordheim, L. & Dumontet, C. Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies. Leuk. Lymphoma 44, 1105-1111 (2003).
25. Pieters, R. et al. Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. Leuk. Res. 16, 873-880 (1992).
26. Allegrini, S. et al. Mechanistic studies on bovine cytosolic 5′-nucleotidase II, an enzyme belonging to the HAD superfamily. Eur. J. Biochem. 271, 4881-4891 (2004).
27. Sanford, M. & Lyseng-Williamson, K.A. Nelarabine. Drugs 68, 439-447 (2008).
28. Berg, S.L. et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J. Clin. Oncol. 23, 3376-3382 (2005).
29. Gökbuget, N. et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 118, 3504-3511 (2011).
30. DeAngelo, D.J. et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109, 5136-5142 (2007).
31. Bhatia, S. et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J. Clin. Oncol. 30, 2094-2101 (2012).
32. Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
33. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830-837 (2011).
34. Pettersen, E.F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
35. Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402 (1997).
36. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725-738 (2010).
37. Worth, C.L., Preissner, R. & Blundell, T.L. SDM-a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res. 39, W215-W222 (2011).